Release date: July 10, 2025
Expiration date: July 9, 2027
Estimated Time of Completion: 2 hours and 45 minutes
Session Agenda
Emerging treatment in small vessel vasculitis
Benjamin Terrier, MD, PhD
Emerging treatment in large vessel vasculitis
Carol Langford, MD, MHS
EGPA - What can I offer to my patients?
Michael Wechsler, MD, MMSc
Central Nervous System involvement in vasculitis
Rula Hajj-Ali, MD
Ask the Masters: Challenging cases in vasculitis
Rula Hajj-Ali, MD, Moderator
Ruoning Ni, MD, Case presenter
Description
Watch Vasculitis 2025: Advances and Controversies on-demand webcast series, recorded from the Vasculitis 2025: Advances and Controversies course. The focus of the education is to review complexities and innovations in the treatment and diagnosis of various forms of vasculitis.
Learning Objectives
- Critically appraise emergent treatment options in small vessel vasculitis and large vessel vasculitis
- Discuss brief overview of large vessel vasculitis.
- Review treatment of giant cell arteritis and Takayasu arteritis.
- Evaluate CNS involvement in vasculitis.
Target Audience
The online series is directed towards rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, nurse practitioners, nurses, and physician assistants interested in the treatment of vasculitis.
Accreditation
In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians / American Medical Association (AMA)
Cleveland Clinic Center for Continuing Education designates this internet enduring activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.
Nurses / American Nurses Credentialing Center (ANCC)
Cleveland Clinic Center for Continuing Education designates this internet enduring activity for a maximum of 2.75 ANCC contact hours.
Physician Assistants / American Academy of PAs (AAPA)
Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Certificate of Participation
A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations.
Activity Director and Faculty
Activity Director
Rula Hajj-Ali, MD
Associate Director, Center for Vasculitis Care and Research
Vice Chair, Medical Specialty Institute
Department of Rheumatic & Immunologic Diseases
Medical Specialty Institute
Cleveland Clinic
Cleveland, OH
Additional Planners
Debra Kangisser, PA-C
Elizabeth (Betsy) Kirchner, DNP
Faculty
Carol Langford, MD, MHS
Director, Center for Vasculitis Care and Research
Department of Rheumatic & Immunologic Diseases
Medical Specialty Institute
Cleveland Clinic
Cleveland, OH
Ruoning Ni, MD
Department of Rheumatic & Immunologic Diseases
Medical Specialty Institute
Cleveland Clinic
Cleveland, OH
Benjamin Terrier, MD, PhD
Université Paris Cité
Paris, France
Michael Wechsler, MD, MMSc
Director, The Cohen Family Asthma Institute
Professor, Department of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Denver, CO
CME Disclaimer
The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.
Faculty Disclosure
In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), Cleveland Clinic Center for Continuing Education mitigates all relevant conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated they have no relationship which, in the context of his/her presentation(s), could be perceived as a potential conflict of interest
Rula Hajj-Ali, MD |
Amgen |
Advisor or review panel participant |
GSK |
Advisor or review panel participant (Ended: 12/01/2022) |
UpToDate, Inc. |
Intellectual property rights (Royalties or patent sales) |
Elizabeth Kirchner, DNP |
Lilly |
Consulting (Ended: 06/29/2023) |
Pfizer
Janssen Pharmaceuticals, Inc. |
Consulting |
RhAPP |
Teaching and Speaking |
Carol Langford, MD |
Bristol-Myers Squibb Co.
GlaxoSmithKline
Abbvie Pharmaceuticals |
Other activities from which remuneration is received or expected |
NS Pharma
AstraZeneca |
Research |
Michael Wechsler, MD |
Astrazeneca Pharmaceuticals |
Consulting
Teaching and Speaking
Research |
Genenetch
Allakos Inc
Areteia Therapeutics
Arrowhead
Avalo Therapeutics
Belenos Bio
Celldex Therapeutics
Connect Biopharma
Eli Lilly
Equillium
Incyte
Jasper Therapeutics
Kinaset
Kymera
Merck
MyBiometry
Pharming
Phylaxis
Pulmatrix
RAPT Therapeutics
recludix
Pharma |
Consulting |
GlaxoSmithKline |
Consulting
Advisor or review panel participant |
Regeneron
Sanofi
Sentien
Tetherex Pharmaceuticals
Uniquity Bio
Verona Pharma
Zurabio
Amgen |
Consulting
Teaching and Speaking |
Upstream Bio |
Consulting
Ownership Interest - Stock Options |
All other individuals have indicated no relationship which, in the context of their involvement, could be perceived as a potential conflict of interest.
Acknowledgment
The Cleveland Clinic Center for Continuing Education acknowledges educational grants for partial support of this activity from:
AstraZeneca Pharmaceuticals
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s Department of Rheumatic & Immunologic Diseases,and Cleveland Clinic’s RJ Fasenmyer Center for Clinical Immunology.